Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics' stock price has significantly declined over the past six months. Key events impacting the stock include reports of ongoing financial challenges and the release of third-quarter 2025 financial results in November 2025. In October 2025, the company announced advancements in its Phase 1 studies for APR-1051 and ATRN-119 and reported promising early results for APR-1051 at the AACR-NCI-EORTC Conference. In June 2025, Aprea Therapeutics reported promising preclinical and initial clinical data for APR-1051 in HPV+ head and neck cancers. In March 2025, the company dosed the first patient with HPV+ HNSCC in the ACESOT-1051 trial and reported quarterly earnings.

As a clinical-stage biopharmaceutical company, Aprea Therapeutics, Inc. is focused on research, development, and clinical trials, and its products are not yet commercialized. Therefore, there is no established demand seasonality for its products or services.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics, specifically synthetic lethality-based treatments targeting DNA damage response pathways. The company's lead product candidates include APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase in Phase 1 clinical trial for advanced solid tumors, and ATRN-119, an ATR inhibitor in Phase 1/2a clinical trials for solid tumor indications. Aprea also has early-stage programs under development, such as ATRN-1051, ATRN-354, and APRE-DDRi, aimed at treating complex solid tumor conditions. The company is headquartered in Doylestown, Pennsylvania.

Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, United States. Its activities are primarily focused on research and development, including clinical trials.

Aprea Therapeutics' brand reputation is shaped by its clinical trial progress and financial performance. Positive news includes the advancement of its dual DDR programs and early signals of drug activity for APR-1051. However, ongoing financial challenges and a significant decline in stock price could negatively impact its reputation.

Aprea Therapeutics' ownership structure is comprised of institutional investors, insiders, and retail investors. Major institutional shareholders include AIGH Capital Management LLC, Sphera Funds Management Ltd., Nantahala Capital Management, LLC, Vanguard Group Inc, DAFNA Capital Management LLC, Sio Capital Management, LLC, Morgan Stanley and Geode Capital Management, Llc. Oren Gilad, the CEO and President, owns the most shares among individual investors, and insiders have purchased more shares than they have sold over the last year.